Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a ...

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ...

All poster presentations will take place in Poster Hall I2 ... BaseCamp is also establishing a comprehensive approach integrating robust process design, clinical insights, and risk-based analysis, ...

A poster presentation will highlight new translational ... In addition, two trials-in-progress presentations will showcase the design and scientific rationale of ongoing clinical studies evaluating ...

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced that it will have four feat ...

ProBio, a global contract development and manufacturing organization (CDMO), announced that it will present six poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th ...

This “trial-in-progress” presentation will focus on the design of the ongoing expansion portion of Mersana’s Phase 1 clinical trial of Emi-Le that is actively enrolling patients with triple ...

today announced the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. In addition to a trial-in-progress study design ...

Cardiff Oncology has sufficient funds to operate until early 2027 but will face funding challenges by 2026. Learn why CRDF ...